- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma Holdings Ltd today announced the signing of an agreement with SSL International plc , owner of Durex(R), the world's leading condom brand.
The agreement, under which a commercial licence will be negotiated, sets out a co-development program for condoms with a VivaGel(R) coating. Undisclosed fees are payable to Starpharma under the co-development agreement, which also provides for the commencement of regulatory and market development activities by the two parties.
SSL is the world's largest manufacturer of condoms with approximately 30% share of the global market for branded condom sales, selling into over 100 countries around the world. Global condom retail sales in 2005 were approximately $3.2 billion(1)(1), with the top four companies representing as much as 70% of the market.
"We are delighted to be working with SSL, whom we believe will be an excellent co-development partner for VivaGel(R) as a condom coating," said Starpharma's Chief Executive Officer, Dr. Jackie Fairley. "In addition to SSL's unparalleled global commercial position and the strength of the Durex(R) brand, Starpharma also values the organisation's innovative approach, and its social-marketing program.
"Our development and commercialisation activities for VivaGel(R) are gathering momentum with this SSL agreement being the second of two unrelated condom coating agreements signed by Starpharma in the last three months," concluded Dr. Fairley.
VivaGel(R) has been shown to have potent contraceptive and microbicidal properties in animal studies, and is also under development as a stand-alone gel to prevent the transmission of STIs, including HIV and genital herpes.
(1)(1) "Condoms: A Global Strategic Business Report", March 2005, Global Industry Analysts Inc.
About Starpharma Holdings Limited
Starpharma Holdings Limited is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc. in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
For more information, please click here
Tel: +61 2 9237 2800
Mob: +61 417 382 391
Dr. Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
+61 3 8532 2702
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Abalonyx launches Reduced Graphene Oxide Product: Abalonyx has successfully scaled up production of thermally reduced graphene oxide (rGO) in its Tofte, Norway, production facility. This product is now offered to customers in Kg-quantities May 10th, 2016
New Generation of Graphene Reinforced Carbon Fibre Prepreg Products March 14th, 2016
New Generation of Graphene Reinforced Carbon Fibre Prepreg Products March 10th, 2016
Novel state of matter: Observation of a quantum spin liquid July 29th, 2016
A new type of quantum bits July 29th, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016
Lonely atoms, happily reunited July 29th, 2016
Ultrasensitive sensor using N-doped graphene July 26th, 2016